Skip to main content

Table 3 The cumulative annual cost - effectiveness and benefit-cost of SIF in Ottawa using the first model

From: A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada

Variables

Annual cost of operation

Sharing rate

# of HIV averted

# of HCV averted

Cost-effectiveness ratio HCV

Cost-effectiveness ratio HIV

Benefit-cost ratio HCV

Benefit-cost ratio HIV

Cost-benefit ratio Total

Post SIF

$2,182,800

11%

5

48

$45,475

$436,560

0.77

0.48

1.26

  

(14%, 7%)

(6, 3)

(65, 31)

($33,581, $70,413)

($363,800, $727,600)

(1.1, 0.5)

(0.58, 0.3)

(1.63, 0.79)

Two SIF

$4,365,600

8%

9

88

$49,609

$485,067

0.71

0.43

1.14

  

(11%, 5%)

(12, 6)

(120, 57)

($36,380, $76,589)

($383,800, $727,600)

(1, 0.46)

(0.58, 0.3)

(1.54, 0.75)

Three SIF

$6,548,400

6%

11

112

$58,468

$595,309

0.6

0.35

0.95

  

(9%, 4%)

(15, 7)

(148, 70)

($44,246, $93,549)

($436,560, $936,486)

(0.8, 0.38)

(0.48, 0.22)

(1.28, 0.6)

Four SIF

$8,731,200

5%

13

129

$67,683

$671,631

0.52

0.31

0.83

  

(7%, 3%)

(17, 8)

(175, 83)

($49,893, $105,195)

($513,600, $1,091,400)

(0.7, 0.33)

(0.41, 0.19)

(1.11, 0.5)

Five SIF

$10,914,000

3%

15

150

$72,760

$727,600

0.48

0.29

0.77

  

(5%, 2%)

(20, 9)

(203, 96)

($53,764, $113,688)

($545,700, $1,212,667)

(0.65, 0.31)

(0.39, 0.17)

(1.04, 0.48)

Six SIF

$13,096,800

2%

17

170

$77,040

$770,400

0.46

0.27

0.73

  

(3%, 1%)

(23, 10)

(232, 110)

($569,426, $119,062)

($569,426, $1,309,680)

(0.62, 0.3)

(0.37, 0.16)

(0.99, 0.46)

Seven SIF

$15,279,600

1%

19

191

$79,998

$804,189

0.44

0.26

0.70

  

(1%, 1%)

(26, 12)

(259, 123)

($58,995, $124,224)

($587,677, $1,273,300)

(0.6, 0.28)

(0.36, 0.16)

(0.55, 0.45)

  1. Note: The numbers in parentheses represent the results of the sensitivity analysis: (19 per cent sharing rate, 9 percent sharing rate).